Treatment of Allergic Rhinitis in Infants (6-12 Months)
For infants aged 6-12 months with perennial allergic rhinitis, montelukast is the only FDA-approved pharmacologic treatment option, while saline nasal irrigation serves as a safe adjunctive therapy. 1
First-Line Pharmacologic Treatment
Montelukast (Leukotriene Receptor Antagonist)
- Montelukast is FDA-approved for perennial allergic rhinitis in children as young as 6 months of age and represents the primary pharmacologic option for this age group 1
- The medication produces statistically significant improvement in nasal symptoms and quality of life scores compared to placebo 1
- Onset of action occurs by the second day of daily treatment 1
- This is particularly valuable when treating infants whose parents are steroid-phobic or when combined upper and lower airway disease is present (up to 40% of allergic rhinitis patients have coexisting asthma) 1
Important Age Restrictions for Other Medications
- Intranasal corticosteroids, while the most effective medication class for allergic rhinitis in older patients, lack specific FDA approval and safety data for infants under 2 years 1
- Second-generation oral antihistamines (cetirizine, desloratadine, fexofenadine, loratadine) have demonstrated good safety profiles in young children but are not routinely recommended for infants 6-12 months 1
- Fexofenadine has been studied in children 6 months to 2 years and showed good tolerability, though it is not FDA-approved for this specific age group 2
Critical Safety Warning: Avoid OTC Cough and Cold Medications
- OTC cough and cold medications should be avoided in all children below 6 years of age due to lack of efficacy and significant safety concerns 1
- Between 1969-2006, there were 54 fatalities associated with decongestants in children ≤6 years (43 were below age 1 year) 1
- During the same period, 69 fatalities were associated with first-generation antihistamines in the same age group (41 below age 2 years) 1
- Drug overdose and toxicity resulted from use of multiple products, medication errors, accidental exposures, and intentional overdose 1
Adjunctive Non-Pharmacologic Treatment
Saline Nasal Irrigation
- Topical saline is beneficial as sole modality or adjunctive treatment for chronic rhinorrhea 1
- Both isotonic and hypertonic saline solutions can be used safely in infants 1
- While less effective than intranasal corticosteroids in older patients, saline represents a safe option for symptom relief in this vulnerable age group 1
Allergen Avoidance
- Environmental controls should be implemented when specific allergens are identified 3, 4
- This includes removal of pets, use of air filtration systems, bed covers, and acaricides for dust mite control 3
Clinical Pitfalls and Caveats
Distinguishing allergic from infectious rhinitis is extremely difficult in infants, as both present with similar symptoms 1. Key considerations:
- Allergic rhinitis typically presents with clear rhinorrhea, nasal congestion, and may have associated eye symptoms 3, 4
- Chronic or recurrent symptoms lasting more than 4 consecutive weeks suggest persistent allergic rhinitis rather than repeated viral infections 5
- Formal allergy testing (skin or specific IgE blood tests) should be considered when diagnosis is uncertain or when empiric treatment fails 3, 4
Seasonal allergic rhinitis distinction: Montelukast is FDA-approved for seasonal allergic rhinitis only in children as young as 2 years, not 6 months 1. For infants 6-12 months, the approval is limited to perennial (year-round) allergic rhinitis.
When to Escalate Care
- If symptoms persist despite montelukast and environmental controls, refer to pediatric allergist for comprehensive evaluation 3, 4
- Assess and document associated conditions including asthma, atopic dermatitis, sleep-disordered breathing, conjunctivitis, and otitis media 3, 4
- Consider that up to 40% of patients with allergic rhinitis develop coexisting asthma, making early identification and treatment crucial 1